Australia, Nov. 25 -- CSL Behring Gene Therapy Inc., owns the trademark (2457763) for 'CYTEGRITY' till Feb. 14, 2034.
Status: protected:
Registered/protected
Classes: 40 [Biomanufacturing for others, namely, manufacturing of pharmaceuticals and of viral vectors and gene therapy vectors; custom manufacturing services of ex vivo, lentiviral stable cell lines; custom manufacturing services of lentiviral vectors by transient transfection; biomanufacturing of viral vectors and gene therapy vectors; biomanufacturing services of cell lines and cells; biomanufacturing of biological preparations.], 42 [Scientific, pharmaceutical and medical research and development; biological research; laboratory services in connection with viral vectors and gene therapy vectors; scientific, pharmaceutical, and medical research platform services featuring bioproduction, regulatory pathway services, accessory proteins and alternative envelope proteins.] and 45 [Regulatory and process pathway consulting for clinical manufacturing.]
Type of Mark: Word
Date of Acceptance: Sept. 17
Registration Advertised: Nov. 24
For further details contact Davies Collison Cave Pty. Ltd. and Scott D. Woldow Smith, Gambrell & Russell LLP .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2457763.
Disclaimer: Curated by HT Syndication.
